BindingDB logo
myBDB logout

78 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27876250 60 Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI Jagiellonian University Medical College
26988801 55 Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI Jagiellonian University Medical College
26741855 65 Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.EBI The University of Sydney
25774991 23 N-benzoyl-1,5-benzothiazepine and its S-oxide as vasopressin receptor ligands: insight into the active stereochemistry around the seven-membered ring.EBI Teikyo University
25654260 49 Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.EBI F. Hoffmann-La Roche Ltd.
25642985 45 Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.EBI UMR7200 CNRS/Universit£ de Strasbourg
24881566 140 Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).EBI GlaxoSmithKline
24874785 333 New, potent, and selective peptidic oxytocin receptor agonists.EBI Ferring Research Institute Inc.
16250654 41 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.EBI GlaxoSmithKline Research and Development
21700453 56 Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.EBI MSD
21458261 55 The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.EBI MSD
21146408 53 The characterization of a novel V1b antagonist lead series.EBI GlaxoSmithKline Research and Development
20674355 58 Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.EBI GlaxoSmithKline
19081251 38 Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.EBI GlaxoSmithKline Pharmaceuticals
22984902 59 Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: application to ligand screening and oligomerization assays.EBI UMR7200 CNRS/Universit£ de Strasbourg
22239250 59 Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.EBI GlaxoSmithKline Research and Development
22425346 28 Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors.EBI Emory University
20104850 48 Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.EBI UMR 7200 CNRS/Universit£ de Strasbourg
19800231 92 Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.EBI Schering-Plough Research Institute
18032036 17 The discovery of GSK221149A: a potent and selective oxytocin antagonist.EBI GlaxoSmithKline Research and Development
17850055 18 Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.EBI INSERM
16297621 17 Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.EBI Wyeth Research
16302826 129 Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.EBI Serono Pharmaceutical Research Institute
15857144 10 Design of benzophenone-containing photoactivatable linear vasopressin antagonists: pharmacological and photoreactive properties.EBI INSERM
15084136 96 Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.EBI Medical College of Ohio
12036367 46 Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.EBI INSERM
11585444 295 From hit to lead. Analyzing structure-profile relationships.EBI F-59000 Lille
15149662 71 Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.EBI Johnson and Johnson Pharmaceutical Research and Development
15125926 88 Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.EBI Johnson& Johnson Pharmaceutical Research& Development
22249122 9 Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.EBI Lehigh University
21885275 65 Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.EBI Pfizer Inc.
21688787 295 New, potent, selective, and short-acting peptidic V1a receptor agonists.EBI Ferring Research Institute Inc.
21605973 69 Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties.EBI Abbott
21601454 26 Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.EBI MSD
21428295 43 Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.EBI INSERM
21353540 55 Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.EBI MSD
20550119 96 Oral oxytocin antagonists.EBI DrugMolDesign
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
20471258 117 Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.EBI Pfizer Global Research and Development
20189387 46 Identification of amide bioisosteres of triazole oxytocin antagonists.EBI Pfizer Global Research and Development
20172721 21 Identification of a urea bioisostere of a triazole oxytocin antagonist.EBI Pfizer Global Research and Development
19963374 68 Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.EBI Pfizer Global Research and Development
19376698 16 Aryloxypyrazines as highly selective antagonists of Oxytocin.EBI Pfizer Global Research and Development
7807119 5 Khusimol, a Non-Peptide Ligand for Vasopressin V1a ReceptorsEBI TBA
18778939 23 Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.EBI Pfizer Global Research and Development
18639455 43 Design and optimization of potent, selective antagonists of Oxytocin.EBI Pfizer Global Research and Development
17963373 36 Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors.EBI AstraZeneca R&D Charnwood
17942308 62 Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.EBI Johnson & Johnson Pharmaceutical Research & Development
17855087 19 Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.EBI Wyeth Research
17234419 79 Azetidinones as vasopressin V1a antagonists.EBI Lehigh University
16876401 48 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity.EBI Jerini AG
16153837 21 (4-Substituted-phenyl)-(5H-10,11-dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators.EBI Wyeth Research
15125974 34 Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.EBI Johnson and Johnson Pharmaceutical Research and Development
14592501 33 2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists.EBI Johnson & Johnson Pharmaceutical Research & Development L.L.C.
12639574 21 Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists.EBI Johnson & Johnson Pharmaceutical Research & Development
12372506 41 Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.EBI Johnson and Johnson Pharmaceutical Research and Development
12036368 59 Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.EBI Yamanouchi Pharmaceutical Co. Ltd.
11992787 37 Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives.EBI GlaxoSmithKline
11087564 30 Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.EBI Otsuka Pharmaceutical Company
10782666 46 The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines.EBI Wyeth-Ayerst Research
10406632 11 4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists.EBI Wyeth-Ayerst Research
10340620 30 Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.EBI Merck Research Laboratories
10197974 22 Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.EBI INSERM
9651149 54 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.EBI Wyeth-Ayerst Research
7473590 37 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.EBI Merck Research Laboratories
12660315 17 Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.BDB LCG Bioscience
11861823 10 Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.BDB Sanofi-Synthelabo Recherche
9864265 14 OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.BDB Second Tokushima Institute of New Drug Research
10482466 32 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.BDB Otsuka Pharmaceutical Co., Ltd
19321349 46 Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.BDB Astellas Pharma Inc.
19900813 12 Optimization of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin V2 receptor agonists and discussion of their binding modes.BDB Astellas Pharma Inc.